Latest Enveda Biosciences news, funding rounds and robotics & AI coverage. $820.9M raised. 1 article tracked by The Robotics Media.
Enveda Biosciences is a clinical-stage AI drug discovery company that mines the chemistry of plants, fungi and other natural sources to identify small-molecule therapeutics. The company combines mass spectrometry data, machine learning and robotic lab automation to characterize molecules found in nature and match them to disease targets.
Its core technology is PRISM, a foundation model trained on more than a billion small-molecule mass spectra that is used to identify and characterize natural compounds far faster than traditional wet-lab methods. Enveda's lead clinical candidate, ENV-294, is a small molecule for atopic dermatitis and asthma that reported positive Phase 1b results in 2026 and has advanced into Phase 2a trials; the company has disclosed a pipeline of roughly ten drug candidates spanning immunology, inflammation, fibrosis, obesity and neurological disease.
Enveda was founded in 2019 by Viswa Colluru and Pieter Dorrestein and is headquartered in Boulder, Colorado, with a second R&D site in Hyderabad, India. The company reached unicorn status with its September 2025 Series D round and was valued at roughly $2 billion following its September 2026 Series E financing.